Announcement PDF ASX RELEASE. 26 August 2025 Emyria to Expand Perth Clinic to Meet Growing Demand and Support National Roll-Out Funded PTSD treatments and rising patient demand are driving Perth clinic expansion and underpinning Emyria’s scalable, capital-light expansion strategy. • First Medibank-funded patients commence care – PTSD therapy now delivered at Emyria’s Perth Clinic under Australia’s first private health insurance program for psychedelic-assisted treatment. • Record monthly activity expected – August dosing sessions forecast to exceed the combined total of the previous four months. • Perth Clinic Capacity Expanding – Workforce and infrastructure growth underway to meet strong patient demand. • Brisbane Launch Progressing – Partnership with Avive Health advancing ahead of first interstate clinic opening. • Scalable, Capital Light Model – Empax platform enables repeatable expansion across Australia. • Revenue Growth Accelerating – Medibank-funded treatments and clinic expansion underpin a growing, recurring revenue base. Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to outline key developments supporting national expansion and revenue growth. First Medibank-Funded Patients Commence Treatment Following Emyria’s landmark agreement with Medibank Private Ltd (ASX: MPL)1, the first Medibank-insured patients have now commenced PTSD therapy at the Perth Clinic. This represents the first time in Australia that psychedelic-assisted care has been delivered under private health insurance coverage. Importantly, the agreement with Medibank validates Emyria’s clinical protocols and provides a scalable reimbursement pathway, significantly reducing the financial barrier for patients while de-risking revenue for the Company. This milestone demonstrates the commercial viability of Emyria’s Empax platform and establishes a precedent for future agreements with other major insurers. Record Demand Accelerating Patient Activity Patient and referrer response has been overwhelmingly positive. In August, Emyria expects to deliver more dosing sessions than in the prior four months combined, underscoring the strong underlying demand for effective, reimbursed mental health treatments. This rapid uptake highlights the scalability of the model and suggests significant revenue growth potential as more clinics come online. Emyria ASX Announcement | 26 Aug 2025 ASX RELEASE. The demand also reflects growing awareness and acceptance among both clinicians and patients, reinforcing Emyria’s first-mover advantage in an emerging sector with few competitors. Sustained growth at this level has the potential to support predictable, recurring revenues and strengthen the Company’s position as the partner of choice for insurers, hospitals, and regulators. Perth Clinic Expansion Underway With availability at the Perth Clinic nearing capacity for the remainder of 2025, Emyria has commenced targeted workforce recruitment and infrastructure expansion to meet demand and sustain growth. Additional psychiatrists, therapists, and support staff are being engaged alongside fit-for-purpose clinical facilities to increase patient throughput. These investments are capital-light and designed to generate a rapid return by directly expanding treatment capacity and revenue. The speed at which Perth Clinic has reached current capacity provides a clear blueprint for future clinic deployments, strengthening confidence in Emyria’s ability to roll out a scalable national network. Brisbane Launch Progressing with Avive Health Emyria is advancing preparations with Avive Health at its Brisbane Hospital site2. This clinic will represent the Company’s first interstate expansion and marks a significant milestone in establishing a national network of Empax clinics. By partnering with leading hospitals such as Avive, Emyria can leverage existing infrastructure and reduce capital requirements while accelerating time-to-market. The Brisbane site also provides a template for future partnerships across Eastern Australia and beyond, supporting a rapid and efficient scale-up strategy. This interstate expansion underpins the Company’s vision to become Australia’s leading provider of evidence-backed, insurer-funded mental health care. Emyria’s Strategic Rationale and National Expansion Vision Mental health is Australia’s leading chronic health concern3 with conditions like PTSD affecting approximately 1 in 11 Australians4, disproportionately affecting women, veterans and first responders. Existing systems are struggling to meet growing demand, creating an urgent and significant need for more effective, scalable and reimbursed treatment models. Emyria has developed a clinically validated, data-driven model designed for capital-light, repeatable expansion. Through the Empax platform, the Company is executing a national rollout to broaden access and deepen engagement with insurers, hospitals, and regulators, as demand accelerates following its landmark reimbursement agreement. Core elements of the strategy include: • • • • • Establishing additional Empax clinics across major metropolitan areas in Eastern Australia. Partnering with leading private hospitals to deliver care. Working with additional health funders to improve affordability and access. Extending the Empax framework to additional high-need indications, beyond PTSD and treatment-resistant depression. Scaling Emyria’s real-world data platform to support health economics, regulatory engagement, funder-backed expansion, and continuous improvement. Emyria ASX Announcement | 26 August 2025 2 ASX RELEASE. References: 1. 2. 3. 4. See ASX release 16 June 2025 See ASX release 29 July 2025 https://www.aihw.gov.au/reports/australias-health/chronic-conditions https://www.aihw.gov.au/reports/mental-health/stress-and-trauma This release has been approved by the Board of Emyria. For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson Executive Chair 1300 436 363 | investors@emyria.com Emyria ASX Announcement | 26 August 2025 3 ASX RELEASE. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: generates Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. informs Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria ASX Announcement | 26 August 2025 4